As the UK sets its sights on becoming the world’s third-largest life sciences economy by 2035, questions around how to turn ambition into reality are growing louder.
United Kingdom
Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.
As the UK sets its sights on becoming the world’s
third-largest life sciences economy by 2035, questions around how
to turn ambition into reality are growing louder.
In a recent article for Life
Sciences Intellectual Property Review (LSIPR), partners Nick McDonald and Gareth Williams weigh in on the challenges and
opportunities shaping the sector. While it is believed that the
UK’s strong research base and biotech clusters provide solid
foundations, there is caution that no single reform will be enough
to reverse the country’s slide in competitiveness. Coordinated
action across funding, regulation, talent, and market access will
be essential to safeguard the UK’s global position.
From stalled investments and regulatory complexity to talent
shortages and pricing pressures, the article explores what’s
holding the UK back, and what needs to change to keep innovation
thriving.
Read the full piece below.
The country has plenty going for it: world-class
universities, the NHS as a platform for innovation, established
pharma clusters, and a strong track record in early-stage
research.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
